Cardiology

Study of abrupt versus gradual reduction of nicotine informs FDA-proposed rule on reducing cigarette nicotine to "minimally addictive" levels.

The heart rhythm specialist with the UVA Advanced Imaging group discussed his team's early successes with Medtronic's heart ablation vest.

In a phase 2/3 trial, the Bayer Pharmaceuticals therapy demonstrated protection from bleeding and patient safety for up to a median of 1.9 years.

Is there a link between vitamin D deficiency and mortality in patients with heart failure? A new study may have the answer. 

Stem cell research from the University of Michigan reveals dangerous cardiac effects of a gene mutation in patients with Dravet syndrome.

How the conflicting results of the ASCEND trial are actually much more determinant than they appear, and critical in the scope of treating comorbidities in patients with diabetes.

In a 15,000-plus patient analysis that spanned more than 7 years, aspirin reduced vascular risks in patients—but also increased their rate of major bleeding events.

Patients administered the FDA-approved therapy reported tripled rates of weight-loss, along with noninferiority for risk of major cardiovascular events, over 1 year and an extension period.

The update reported significant improvements in future cardiovascular risks in patients at risk for chronic angina initially referred for CTA plus standard care, versus those only referred to standard care.

In an analysis of 118 clinical trials since 2001, investigators found females and minorities comprised just 27% and 22% of the total patient population, respectively.

Compared to those with LDL cholesterol levels 160 mg/dL had a 70-90% increased risk.

A new study suggests that subclinical RV dysfunction may cause exercise-induced dyspnea in compensated subjects with PAH.

Treating patients with methamphetamine-associated PAH presents unique challenges including the pros and cons of placing venous access ports.

The celebrity chef-turned-producer wants to champion healthcare access, both on the screen and in person. Where does he start?

This combination of telmisartan, amlodipine, and chlorthalidone reduced blood pressure to target levels in 69.5% of patients at 6 months, compared to 55.3% of patients receiving usual care.

Galafold differs from common enzyme replacement therapy in that it increases the activity of the body’s deficient enzyme.

For patients with acute coronary syndrome and depression, taking escitalopram to treat depression resulted in significantly fewer major cardiac events compared to patients given placebo.

Women and men are more likely to survive when treated by female doctors compared to male doctors, but the difference in heart attack survival is greater for women.

Researchers were able to rule out myocardial infarction in 30% of patients immediately, and another 25% of patients at 1 hour. By 3 hours, the assay had successfully ruled out MI in 83.8% of patients, versus the 80.4% ruled out under the conventional assay.

Research suggests that elevated glycemia, low blood pressure, and low BMI may be identifying markers for dementia risk and possible targets for management or prevention.

The optimal duration of dual antiplatelet therapy remains unclear, despite being proven efficacious for roughly 2 decades.

Patients in the intensive blood pressure treatment group had a 19% lower risk of developing mild cognitive impairment compared to those given standard treatment, according to the SPRINT MIND study.

Patient history includes right heart failure due to sinus venosus defect with anomalous right pulmonary venous return; surgical repair performed ca 2006.

Does caffeine increase or decrease the risk of new onset AF? Find out with our T/F quiz on results of a new meta-analysis.

The PocketECG Cardiac Rehabilitation System provides electrocardiography (ECG) monitoring and alerts during cardiac rehabilitation.

Phase 2a clinical trial commences for repurposed drug, SOM3355, for the treatment of Huntington’s disease.

A review of literature on depression and anxiety in patients with heart failure reports that 21.5% have depressive symptoms and 19% meet the criteria for a depressive disorder—2 to 3 times higher than rates in the general population.

The paradigm of obesity is complex and requires a multi-disciplinary approach, but it is one of the most gratifying experiences for both the physicians and patient when they see the results of weight loss.

Results showed that participants with doctor-diagnosed asthma had a 38% increased risk of developing AF compared to those without asthma.

Certain lots of the therapy, distributed under the Actavis label in the US, have been detected to have trace amounts of probably human carcinogen NDMA.